Skip to main content
. 2013 Aug 6;2013(8):CD005151. doi: 10.1002/14651858.CD005151.pub2

1. Haemodynamic outcome measures for comparator interventions reported by only one trial.

Change in SBP after 30 minutes
Study ID Number of participants Comparator interventions Measure of effects
Nelson 1983 28 ISDN versus frusemide Fixed‐effect MD ‐6.00 mmHg, 95% CI ‐10.51 to ‐1.49
Beltrame 1998 69 NTG/NAC versus frusemide/morphine Fixed‐effect MD ‐2.00 mmHg, 95% CI ‐21.49 to 17.49
Change in SBP after 60 minutes
Study ID Number of participants Comparator interventions Measure of effects
Nelson 1983 28 ISDN versus frusemide Fixed‐effect MD ‐10.00 mmHg, 95% CI ‐12.62 to ‐7.38
Beltrame  1998 69 NTG/NAC versus frusemide/morphine Fixed‐effect MD ‐4.00 mmHg, 95% CI ‐23.75 to 15.75
Change in SBP after 3 hours
Study ID Number of participants Comparator interventions Measure of effects
VMAC 2002 285 NTG versus placebo Fixed‐effect MD ‐3.20 mmHg, 95% CI ‐6.19 to ‐0.21
VMAC 2002 347 NTG versus nesiritide Fixed‐effect MD ‐3.05 mmHg, 95% CI ‐3.05 to 2.85
Beltrame 1998 69 NTG/NAC versus frusemide/morphine Fixed‐effect MD ‐2.00 mmHg, 95% CI ‐21.32 to 17.32
Change in SBP after 24 hours
 Study ID Number of participants Comparator interventions Measure of effects
Beltrame 1998 69 NTG/NAC versus frusemide/morphine Fixed‐effect MD ‐3.00 mmHg, 95% CI ‐21.94 to 15.94
Change in DBP after 30 minutes
Study ID Number of participants Comparator interventions Measure of effects
Nelson 1983 28 ISDN versus frusemide Fixed‐effect MD ‐3.00 mmHg, 95% CI ‐5.22 to ‐0.78
Change in DBP after 60 minutes
Study ID Number of participants Comparator interventions Measure of effects
Nelson 1983 28 ISDN versus frusemide Fixed‐effect MD ‐5.00 mmHg, 95% CI ‐7.22 to ‐2.78
Change in HR after 30 minutes
Study ID Number of participants Comparator interventions Measure of effects
Nelson 1983 28 ISDN versus frusemide Fixed‐effect MD 0.00 bpm, 95% CI ‐3.35 to 3.35
Beltrame 1998 69 NTG/NAC versus frusemide/morphine No significant difference reported
Change in HR after 60 minutes
Study ID Number of participants Comparator interventions Measure of effects
Nelson 1983 28 ISDN versus frusemide Fixed‐effect MD 1.00 bpm, 95% CI ‐2.35 to 4.35
Beltrame 1998 69 NTG/NAC versus frusemide/morphine No significant difference reported
Change in HR after 3 hours
Study ID Number of participants Comparator interventions Measure of effects
Beltrame 1998 69 NTG/NAC versus frusemide/morphine Fixed‐effect MD ‐2.00 bpm, 95% CI ‐15.54 to 11.54
Change in HR after 24 hours
Study ID Number of participants Comparator interventions Measure of effects
Beltrame 1998 69 NTG/NAC versus frusemide/morphine Fixed‐effect MD 10.00 bpm, 95% CI ‐2.78 to 22.78
Change in PAOP after 3 hours
Study ID Number of participants Comparator interventions Measure of effects
VMAC 2002 122 NTG versus placebo Fixed‐effect MD ‐1.80 mmHg, 95% CI ‐3.50 to ‐0.10
VMAC 2002 184 NTG versus nesiritide Fixed‐effect MD 2.00 mmHg, 95% CI 0.24 to ‐3.76
Change in PAOP after 18 hours
Study ID Number of participants Comparator interventions Measure of effects
Verma 1987 24 ISDN versus frusemide Fixed‐effect MD 2.00 mmHg, 95% CI ‐3.34 to 7.34
Change in PAOP after 24 hours
Study ID Number of participants Comparator interventions Measure of effects
VMAC 2002 246 NTG versus nesiritide Mean reduction in PAOP was significantly greater with nesiritide (‐8.2 mmHg) than with NTG (‐6.3; P = 0.04)
Change in CO after 3 hours
Study ID Number of participants Comparator interventions Measure of effects
VMAC 2002 184 NTG versus placebo Fixed‐effect MD 0.20 L/min/m2, 95% CI 0.00 to 0.40
VMAC 2002 184 NTG versus nesiritide Fixed‐effect MD 0.10 L/min/m2, 95% CI ‐0.05 to ‐0.25

bpm: beats per minute
CI: confidence interval
CO: cardiac output
HR: heart rate
ISDN: isosorbide dinitrate
MD: mean difference
NAC: N‐acetylcysteine
NTG: nitroglycerin
PAOP: pulmonary artery occlusion pressure
SBP: systolic blood pressure